The March, 2026, decision by the French drug regulatory agency to approve intravenous racemic ketamine for the treatment of adult severe suicidal crisis1 represents a major step forward in the ...

Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong ...

Oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and ...

New medicine piggybacks onto fat absorption pathways to allow oral delivery and support clinical trial in major depressive disorder; New medic ...

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption ...

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto ...

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption ...

The global animal drug compounding market is growing steadily, expected to be valued at around US$1.5 in 2026 and projected ...

Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors ...

March 2 (Reuters) - (This March 2 story has been corrected to say FDA decision is expected in early second quarter, not April, in the first bullet point) Eli Lilly (LLY.N), opens new tab CFO ‌Lucas ...

Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary ...

Feb 25 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for ...